Single-Cell Pluripotent Stem Suspension Culture Without Cell Clumps
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for culturing pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPS cells, are not scalable, require animal-derived components, and lack efficient methods for maintaining undifferentiated states in suspension cultures.
Innovation Solution
A method involving mechanical dissociation of pluripotent stem cell clumps to single cells in a suspension culture, using a defined medium devoid of substrate adherence, and specific growth factors like bFGF, IL6RIL6 chimera, and IL11, to maintain undifferentiated pluripotent stem cells without enzymatic dissociation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pluripotent stem cells are cultured using traditional methods with feeder layers and animal-derived components, then the cells can be maintained in an undifferentiated state, but the culture system is not scalable and contains xeno-components that limit clinical applications
Solution Approach 1:
The invention extracts and removes animal-derived components (xeno-components) and feeder layers from the culture system, replacing them with defined, xeno-free culture media containing specific growth factors. This extraction enables clinical applicability while maintaining the undifferentiated state through chemically defined conditions rather than biological layers.
Solution Approach 2:
The invention changes the cultural parameters from undefined, animal-derived media to fully defined, xeno-free media with specific concentrations of growth factors (bFGF, IL-6, LIF). This parameter change enables both scalability for industrial production and clinical safety while preserving stem cell pluripotency through optimized chemical conditions.
2Ease of operation
If pluripotent stem cells are cultured in suspension as clumps, then the cells can be maintained with simpler procedures, but the cells cannot be efficiently expanded at single-cell level for clinical applications
Solution Approach 1:
The invention segments the culture approach by maintaining cells in suspension as dispersed single cells rather than as aggregated clumps. This segmentation, combined with specific culture media containing ROCK inhibitors and growth factors, prevents cell death typically associated with single-cell suspension and enables efficient expansion while simplifying the culture procedure through non-adherent conditions.
3Productivity
If enzymatic dissociation is used to passage pluripotent stem cells, then the cells can be separated efficiently, but the enzymatic treatment may compromise cell viability and pluripotency
Solution Approach 1:
The invention replaces enzymatic dissociation (chemical system) with mechanical dissociation methods such as gentle pipetting or filtration. This substitution, combined with culture media containing ROCK inhibitors and growth factors, maintains cell viability and pluripotency while achieving sufficient cell separation for passage, avoiding the harmful effects of enzymatic treatment.
Data Source
AI summary
Provided is an isolated population of human pluripotent stem cells comprising at least 50% human pluripotent stem cells characterized by an OCT4+/TRA1-60−/TRA1-81−/SSEA1+/SSEA4− expression signature, and novel methods of generating and maintaining same in a pluripotent, undifferentiated state a suspension culture devoid of cell clumps. Also provided are novel culture media, cell cultures and methods for culturing pluripotent stem cells in a suspension culture or a two-dimensional culture system while maintaining the cells in a proliferative, pluripotent and undifferentiated state. The novel culture media comprise interleukin 11 (IL11) and Ciliary Neurotrophic Factor (CNTF); bFGF at a concentration of at least 50 ng/ml and an IL6RIL6 chimera; or an animal contaminant-free serum replacement and an IL6RIL6 chimera. Also provided are methods for generating lineage-specific cells from the pluripotent stem cells.